Relationship between Diagnostic Disclosure, Patient Characteristics and Diet Compliance among 1 Month after Radical Operation for the Patients with Middle and Low Differentiated Gastric Cancer

Qing Zhang#, Hai-Yan Hu#, Yu-Ting Xu, Dong-Xue Wang, Yan-Jun Wang and Jia-Nan Sun*

Department of Gastroenterological Surgery, Jilin University First Hospital, Changchun, China
#These authors contributed equally to this work

^*Correspondance to: Jia-Nan Sun 

 PDF  Full Text DOI: 10.25107/2474-1647.3462

Abstract

Background: For patients with middle and low differentiated gastric cancer, will probably require postoperative adjuvant radiation therapy and chemotherapy at 1 month, so it is very important to improve the nutritional status by adjusting diet as advised by the doctor and nurse. Previous research was very little around the influence of diagnostic disclosure on diet compliance. The purpose of our study is to explore the relationship between the diagnostic disclosure and diet compliance. Methods: On the third day after operation, we obtained the general information and diagnostic disclosure status from the patients and their families. The diet compliance was evaluated through reexamination or telephone follow-up 1 month after operation. Results: Patients of knowing the diagnosis comprised 29.13% of the study sample. The diagnostic disclosure was significantly associated with age and family history. After the multivariate adjustment, the disclosure diagnoses is closely related to diet compliance (OR=5.701, 95% CI 2.336-13.915, P ≤ 0.001). Conclusion: The disclosure diagnoses was an important influence factor for diet compliance in patients with gastric cancer, the results provide important implications for China clinicians concerning the practice of diagnostic disclosure of gastric cancer to patients.

Keywords

Cite the article

Zhang Q, Hu H-Y, Xu Y-T, Wang D-X, Wang Y-J, Sun J-N. Relationship between Diagnostic Disclosure, Patient Characteristics and Diet Compliance among 1 Month after Radical Operation for the Patients with Middle and Low Differentiated Gastric Cancer. Clin Surg. 2022; 7: 3462..